gut microbiota and response to immunotherapeutic drugs in oncology: more questions than answers
Clicks: 274
ID: 129908
2020
Article Quality & Performance Metrics
Overall Quality
Improving Quality
0.0
/100
Combines engagement data with AI-assessed academic quality
Reader Engagement
Star Article
81.0
/100
267 views
219 readers
Trending
AI Quality Assessment
Not analyzed
Abstract
Immuno-oncology drugs (IODs) have revolutionized the treatment of some cancers. Although IODs are enabling some patients with cancer to become long-time survivors, only 30% to 40% respond to these drugs. There is experimental and clinical evidence that the gut microbiome may play a role in IOD response, leading to speculation that manipulation of the gut microenvironment might improve the response rate to IODs. We review the evidence relating to how gut microorganisms may affect response to IODs and discuss the implications of targeting the microbiome to improve IOD response, including the challenges to refine and translate the findings to practical clinical use.
| Reference Key |
abhyankar2020clinicalgut
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Dhiraj Abhyankar;Kelly T McKee;Pavle Vukojevic |
| Journal | clinical medicine insights: oncology |
| Year | 2020 |
| DOI |
10.1177/1179554920933868
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.